Weekly Feature | Nasdaq Dorsey Wright

Weekly Feature

Published: December 26, 2025

This content is for informational purposes only. This should not be construed as solicitation. The general public should consult their financial advisor for additional information related to investment decisions.

With no changes to any of the iShares models, we take a look at the iShares Biotechnology ETF (IBB).

There are no changes to any of the iShares models this week. As we discussed in last Thursday’s report, we have recently seen significant improvement in biotechnology and healthcare, which now have the two highest score directions out of all 134 groups in the Asset Class Group Scores. Investors interested in allocating towards this strength may wish to consider the iShares Biotechnology ETF (IBB). IBB currently has a near-perfect 5.67 fund score and a positive 4.78 score direction. On its default chart, IBB has completed two consecutive buy signals and reached a new multi-year high last month.

The fund currently sits in heavily overbought territory, with a weekly overbought/oversold (OBOS) reading of 72%, so those looking to add exposure may be best served to look for a pullback into the upper $160s or wait for prices to normalize around current levels. IBB has most recently found support at $166. Year-to-date (through 12/24) IBB has gained 31% on a price return basis.

Back to report

DISCLOSURE

**Unless otherwise stated, the performance numbers herein are based on price returns and do not include dividends or all transaction costs. Past performance is not indicative of future results. Potential for profits is accompanied by possibility of loss. BlackRock sponsors the Dorsey Wright iShares ETF Models. However, analysis, models and recommendations are created and provided solely by Dorsey, Wright & Associates (Dorsey Wright). Neither BlackRock, BlackRock Advisors and its affiliates, nor SEI Investments Distribution Co. or its affiliates (SEI) are affiliated with Dorsey Wright. Neither BlackRock nor SEI provides investment advice or recommendations regarding any security, fund or market. Analysis, models and recommendations should not be considered an offer to purchase or sell, or a solicitation of an offer to buy or purchase any security, including iShares. The examples presented do not take into consideration commissions, tax implications, or other transactions costs. No individual risk management tools are used in maintaining this model. This model may not be suitable for all investors. As the investment professional making the final decision with respect to allocations, remember to adhere to NASD Rules 2090 and 2111 (formerly NYSE Rule 405, Know Your Customer). The percentage of the portfolio devoted to any iShares strategy, as well as final individual weightings are at the sole discretion of the financial advisor and not Dorsey, Wright & Associates, BlackRock or SEI Investments Distribution Co. or its affiliates (SEI) . If you are not familiar with the Point & Figure methodology, we suggest you read "Point & Figure Charting, 4th Edition" by Thomas J. Dorsey or visit the PnF University at www.dorseywright.com. If you are not familiar with the iShares products, or Exchange Traded Funds (ETFs), we suggest you visit www.ishares.com for more information.